UroStream

Urothelial carcinoma (UC) is a highly aggressive malignancy with high incidence and severe complications, significantly impacting patients’ quality of life and survival outcomes. In recent years, there have been remarkable advances in both the diagnosis and treatment of UC. At the 2025 Pujiang Uro-Oncology Conference—jointly organized by the CSCO Urothelial Carcinoma Expert Committee, CSCO Renal Cancer Expert Committee, the Chinese Urologic Oncology Cooperative Group, the Beijing Health Promotion Association Chen Jumei Public Welfare Foundation, and the Shanghai Urologic Oncology Institute, and co-organized by Fudan University Cancer Hospital—Professor Jinchun Xing of the First Affiliated Hospital of Xiamen University delivered an insightful lecture on the latest breakthroughs and future directions in UC management.

At the recently concluded 2025 Pujiang Uro-Oncology Conference, the “High-Quality Development Forum on Urologic Oncology” drew considerable attention as leading domestic and international experts shared cutting-edge clinical and translational research progress. Professor Zhuowei Liu from Sun Yat-sen University Cancer Center (SYSUCC) was invited to present his team’s series of innovative studies in the field of urothelial carcinoma (UC). His talk systematically showcased how investigator-initiated trials (IITs)—ranging from refinements in radical surgery to mechanistic studies of therapeutic resistance—are driving meaningful change in clinical practice and advancing the field.

In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang Uro-Oncology Conference, Professor Qing Zou of Jiangsu Cancer Hospital shared the latest developments in the diagnosis and treatment of representative urologic tumors such as kidney cancer and non–muscle-invasive bladder cancer (NMIBC). He also discussed the implementation of innovative technologies, MDT collaboration, and the experience of building a full-course management system.

We are excited to share the upcoming Pujiang Genitourinary Oncology Academic Conference 2025 Webinar taking place on August 27, 2025. 14:00–15:30 (Dublin/London) | 15:00–16:30 CET | 21:00–22:30 CST This online…

On July 10–11, 2025, Professor Steven Campbell, Chair of Urology at West Virginia University, visited the Sun Yat-sen University Cancer Center (SYSUCC) for a two-day academic exchange. His visit brought an international, cutting-edge perspective to SYSUCC’s Department of Urology while also showcasing the department’s achievements to peers worldwide.

From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.

Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.

A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.

The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, in collaboration with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Centered around the theme “Global Wisdom, Chinese Practice, Precision Breakthroughs,” the event brought together leading experts to discuss cutting-edge progress and clinical insights in prostate cancer care. In an exclusive interview with Oncology Frontier – Urology Frontier, Professor Xiaojian Qin of Fudan University Shanghai Cancer Center shared his views on how the guiding philosophy in prostate cancer treatment is evolving.